Amivantamab Lazertinib EGFR NSCLC Clinical Trial Registration
Summary
ClinicalTrials.gov registered a Phase 2 clinical trial (NCT07507188) evaluating amivantamab in combination with lazertinib for treatment of EGFR-mutated non-small cell lung cancer (NSCLC). The single-center study is sponsored by Yonsei University in South Korea. This registration provides public disclosure of the trial's existence, design, and recruitment status.
What changed
ClinicalTrials.gov recorded a new clinical trial registration (NCT07507188) for a Phase 2 study investigating amivantamab combined with lazertinib in participants with EGFR-mutated NSCLC at Yonsei University. The registration includes standard trial metadata such as intervention details, eligibility criteria, and current recruitment status.
Clinical trial sponsors and investigators should ensure their trials meet mandatory registration requirements under FDAAA 801 if applicable. No immediate compliance action is required from this registration entry. Institutions should maintain accurate and current enrollment status updates in the registry as required by applicable regulations.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Named provisions
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.